Resonant Capital Advisors LLC Grows Position in AstraZeneca PLC $AZN

Resonant Capital Advisors LLC raised its position in AstraZeneca PLC (NASDAQ:AZN) by 23.5% in the second quarter, Holdings Channel reports. The fund owned 3,918 shares of the company’s stock after buying an additional 745 shares during the period. Resonant Capital Advisors LLC’s holdings in AstraZeneca were worth $274,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Larson Financial Group LLC lifted its position in shares of AstraZeneca by 297.9% during the 1st quarter. Larson Financial Group LLC now owns 386 shares of the company’s stock worth $28,000 after purchasing an additional 289 shares during the last quarter. Richardson Financial Services Inc. raised its stake in AstraZeneca by 59.8% in the second quarter. Richardson Financial Services Inc. now owns 398 shares of the company’s stock valued at $28,000 after buying an additional 149 shares in the last quarter. Costello Asset Management INC purchased a new stake in AstraZeneca during the 1st quarter worth about $29,000. Maseco LLP acquired a new position in shares of AstraZeneca during the 2nd quarter worth about $34,000. Finally, Caitong International Asset Management Co. Ltd purchased a new position in shares of AstraZeneca in the 1st quarter valued at about $37,000. 20.35% of the stock is owned by hedge funds and other institutional investors.

AstraZeneca Price Performance

Shares of NASDAQ:AZN opened at $84.06 on Tuesday. AstraZeneca PLC has a one year low of $61.24 and a one year high of $86.57. The stock has a market capitalization of $260.70 billion, a price-to-earnings ratio of 31.60, a PEG ratio of 1.54 and a beta of 0.36. The company has a 50-day simple moving average of $80.97 and a 200-day simple moving average of $74.58. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.67 and a current ratio of 0.86.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Tuesday, July 29th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.09. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The firm had revenue of $14.46 billion for the quarter, compared to analysts’ expectations of $14.08 billion. During the same quarter in the previous year, the firm posted $1.24 EPS. The firm’s revenue for the quarter was up 16.1% on a year-over-year basis. On average, analysts predict that AstraZeneca PLC will post 4.51 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on AZN shares. Deutsche Bank Aktiengesellschaft downgraded AstraZeneca from a “hold” rating to a “sell” rating in a report on Thursday, October 16th. Jefferies Financial Group started coverage on shares of AstraZeneca in a report on Monday. They issued a “buy” rating for the company. Berenberg Bank set a $97.00 price target on shares of AstraZeneca in a research note on Wednesday, July 9th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of AstraZeneca in a research report on Wednesday, October 8th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $86.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.